TABLE 1.
Baseline characteristics by receipt of guideline-concordant versus guideline-discordant care
| Total (n = 13,462) | Guideline-discordant (n = 3996) | Guideline-concordant (n = 9466) | P value | |
|---|---|---|---|---|
| Patient characteristics | ||||
| Age, y | <.001 | |||
| <50 | 783 (5.8%) | 158 (4.0%) | 625 (6.6%) | |
| 50–59 | 2960 (22.0%) | 558 (14.0%) | 2402 (25.4%) | |
| 60–69 | 4844 (36.0%) | 1197 (30.0%) | 3647 (38.5%) | |
| 70–79 | 3946 (29.3%) | 1477 (37.0%) | 2469 (26.1%) | |
| >79 | 929 (6.9%) | 606 (15.2%) | 323 (3.4%) | |
| Female | 6523 (48.5%) | 1855 (46.4%) | 4668 (49.3%) | .002 |
| Race | .093 | |||
| White | 11,728 (87.7%) | 3503 (88.4%) | 8225 (87.4%) | |
| Black | 1213 (9.1%) | 327 (8.3%) | 886 (9.4%) | |
| Other | 432 (3.2%) | 133 (3.4%) | 299 (3.2%) | |
| Charlson Comorbidity Score | <.001 | |||
| 0 | 6939 (51.5%) | 1939 (48.5%) | 5000 (52.8%) | |
| 1 | 4815 (35.8%) | 1489 (37.3%) | 3326 (35.1%) | |
| 2+ | 1708 (12.7%) | 568 (14.2%) | 1140 (12.0%) | |
| Education quartile | <.001 | |||
| Bottom | 2166 (16.3%) | 722 (18.3%) | 1444 (15.4%) | |
| Second | 3723 (28.0%) | 1127 (28.6%) | 2596 (27.7%) | |
| Third | 4454 (33.5%) | 1256 (31.9%) | 3198 (34.1%) | |
| Top | 2963 (22.3%) | 834 (21.2%) | 2129 (22.7%) | |
| Income quartile | .001 | |||
| Bottom | 2482 (18.7%) | 805 (20.5%) | 1677 (17.9%) | |
| Second | 3233 (24.3%) | 974 (24.8%) | 2259 (24.1%) | |
| Third | 3704 (27.9%) | 1075 (27.3%) | 2629 (28.1%) | |
| Top | 3879 (29.2%) | 1081 (27.5%) | 2798 (29.9%) | |
| Insurance | <.001 | |||
| Private | 4895 (36.4%) | 1042 (26.1%) | 3853 (40.7%) | |
| Medicare/Medicaid | 7953 (59.1%) | 2778 (69.5%) | 5175 (54.7%) | |
| Other government | 145 (1.1%) | 51 (1.3%) | 94 (1.0%) | |
| Unknown | 134 (1.0%) | 32 (0.8%) | 102 (1.1%) | |
| Uninsured | 335 (2.5%) | 93 (2.3%) | 242 (2.6%) | |
| Tumor characteristics | ||||
| Tumor size, mm, median (IQR) | 33 (23.0, 48.0) | 34 (24.8, 49.0) | 33 (23.0, 48.0) | .318 |
| Clinical T stage | .018 | |||
| T1 | 5710 (42.4%) | 1672 (41.8%) | 4038 (42.7%) | |
| T2 | 6634 (49.3%) | 2027 (50.7%) | 4607 (48.7%) | |
| T3 | 1118 (8.3%) | 297 (7.4%) | 821 (8.7%) | |
| Clinical N stage | .042 | |||
| N0 | 8076 (60.0%) | 2344 (58.7%) | 5732 (60.6%) | |
| N1 | 5386 (40.0%) | 1652 (41.3%) | 3734 (39.4%) |
IQR, Interquartile range.